drugset / Trial / NCT05525715
A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a phase Ib/II, randomized, double-blind, placebo-controlled, parallel, multicenter study of a certain phase to evaluate the efficacy, safety, and pharmacokinetic characteristics of QY201 tablet in subjects in moderate to severe atopic dermatitis
Timeline
- Start
- 2022-10
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QY201 | Unknown | 2 mg | — |
| Subject | QY201 | Unknown | 5 mg | — |
| Subject | QY201 | Unknown | 10 mg | — |
| Subject | QY201 | Unknown | 15 mg | — |
| Subject | QY201 | Unknown | 20 mg | — |